Kyle Munz on Muck Rack

Kyle Munz

Verified
United States
As seen in: American Journal of Managed Care, MJH Life Sciences, NewsBreak, Dermatology Times, Managed Healthcare Executive, Our Community Now, Drug Topics, Patient Care, Formulary Watch
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kyle

Contact Kyle, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Collaboration Advances Lymphoma Care: Andrew Evens, DO

|
By Kyle Munz Verified
| businessandamerica.com
Collaborative efforts between pediatric and adult oncologists are helping shape a bright future for adult and young adult (AYA) patients with Hodgkin and non-Hodgkin lymphoma alike.
Open in Who Shared View Duplicates (2) Issue with article?

Striving for Health Equity: Antoine Keller, MD

|
By Kyle Munz Verified
| businessandamerica.com
US health policy is poised for significant transformation in the years ahead, Antoine Keller, MD, FACC, FACS, a cardiothoracic surgeon at Ochsner Lafayette General Hospital, and founder of HeartSense, told The American Journal of Managed Care®. While shifting legislative agendas will help drive systemwide change, Keller emphasized that clinicians and providers must ultimately define what is truly valuable in health care.
Open in Who Shared Issue with article?

Semaglutide Shows Promise for MASH Resolution, Severe Fibrosis: Naim Alkhouri, MD

|
By Kyle Munz Verified
| businessandamerica.com
Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide (Ozempic), are yet to receive FDA approval for the treatment of metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH). Multiple ongoing trials, however, are demonstrating the great potential for these drugs to influence MASH resolution and benefit those with more severe fibrosis.
Open in Who Shared View Duplicates (6) Issue with article?
See all 78 licensed articles (519 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified